Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
TAIPEI, Taiwan, Jan. 05, 2018 -- TLC (4152.TWO) today announced that it will be attending the 36th annual JP Morgan Healthcare Conference in San Francisco on January 7-11, 2018. TLC President George Yeh will be presenting company updates from Victor’s on the 32nd floor of the Westin St. Francis on Wednesday, January 10 at 3:00pm PT as a part of the Emerging Markets Track.
2018 marks TLC’s fourth consecutive attendance at the invitation-only event, which is the largest and most informative healthcare investment symposium in the industry, with over 400 companies and over 8,000 registered attendees. A copy of Mr. Yeh’s presentation on TLC’s innovative solutions to pain management, ophthalmology and oncology will be available online at http://www.ir-cloud.com/taiwan/4152/irwebsite/event.php.
About TLC
TLC is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine its proprietary lipid-assembled drug delivery platform (LipAD™) with approved active pharmaceutical ingredients. TLC believes that its extensive experience with liposome science allows a combination of speed of onset and benefit duration and improved API concentrations at target tissues while decreasing unwanted systemic exposures. TLC’s BioSeizer™ lipid formulation technology enables local sustained release of APIs at the site of disease or injury, while NanoX™ targeted delivery technology enables prolonged pharmacokinetic profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. These technologies can be used with a broad range of APIs with a simplified and scalable manufacturing process. TLC has a diverse portfolio of product candidates that target significant areas of unmet medical need in pain management, ophthalmology, and oncology, with four candidates expected to be in pivotal clinical trials by 2019. TLC is consistently ranked in the top 5% among all TPEx-listed companies in Taiwan’s Corporate Governance Evaluations.
For more information, please visit the TLC website www.tlcbio.com.
Contact: Dawn Chi Corporate Communications Tel: +886 (0)2 2655 7377 ext 136 Email: [email protected]
